Corient Private Wealth
XENE icon

Corient Private Wealth’s Xenon Pharmaceuticals XENE Stock Holding History

Corient Private Wealth’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Buy
28,732
+430
+2% +$23.9K ﹤0.01% 1481
2026
Q1 		$1.65M Buy
+28,302
New +$1.3M ﹤0.01% 1370

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Corient Private Wealth's XENE Position: Q2 2026 in Review

Corient Private Wealth increased its Xenon Pharmaceuticals (XENE) stake by 1.5% in Q2 2026, buying an estimated $23.9K and bringing the position to 28,732 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Corient Private Wealth first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Corient Private Wealth held 28,732 shares of Xenon Pharmaceuticals worth $1.73M as of Q2 2026.
  • Corient Private Wealth bought 430 Xenon Pharmaceuticals shares in Q2 2026, an estimated $23.9K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1481 holding.
  • Corient Private Wealth first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.